Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Reducing immunosuppression and using antiviral creams improved the woman's skin condition.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.

Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.

A new form of lipodystrophy in HIV patients causes neck fat buildup.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Pexidartinib often causes liver issues and fatigue, especially in women.

Alopecia universalis can be an early sign of HIV.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.

Daprodustat, combined with PAβN, could be a new antibacterial treatment.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.